Retrophin Inc said its drug for a rare kidney disorder, which has no specific treatment, was found safe and effective in a mid-stage study, sending the company’s shares soaring as much as 44 percent on Wednesday.
Analysts said the efficacy and safety profile of the drug, sparsentan, exceeded expectations, keeping them optimistic about the possibility of an accelerated approval for a drug they estimate could rake in up to $1 billion in peak sales.
Source: Reuters
Filed Under: Drug Discovery